•For the first time, the FDA has approved a clinical trial of a secular, ritual-based group facilitation model for psychedelic therapy, demonstrating its safety and efficacy.

•A study on psilocybin therapy for metastatic cancer patients with anxiety and depression showed statistically and clinically significant decreases in symptoms.

•The facilitation model is based on anthropological studies of ritual, specifically rites of passage, to create a secular ritual with therapeutic aims.

•The three phases of the rite of passage—separation, liminal, and reincorporation—correspond to preparation, the psilocybin dosing session, and integration.

•Group models for psilocybin therapy may increase access and offer the unique benefits of community support.

People grappling with the immense emotional and existential weight of a metastatic cancer diagnosis, often have accompanying anxiety and depression that can be as debilitating as the disease itself. Traditional treatments often fall short in addressing this profound distress. However, a pioneering study offers a new ray of hope, exploring the potential of psilocybin-assisted group therapy within a structured, ritual-based retreat setting. For the first time, the FDA has approved a clinical trial of a secular, ritual-based group facilitation model for psychedelic therapy, which has been shown to be both safe and effective (1).

This innovative approach, detailed in a 2026 study in Psychedelic Medicine, involved a Phase 1/2 clinical trial with people with metastatic cancer suffering from moderate to severe anxiety or depression. The results were remarkable, with participants reporting a statistically and clinically significant decrease in their symptoms after a 3-day, in-person retreat where psilocybin was administered (1). This finding is consistent with a growing body of research suggesting that psilocybin therapy can be a powerful tool for cancer patients. A 2024 study in Cancer also found psilocybin-assisted group therapy to be safe and feasible for patients with cancer and depression (2), while a 2023 pilot study in the Journal of Pain and Symptom Management showed possible efficacy for the same demographic (3).

How Does a Ritual-Based Group Retreat Work?

The facilitation model is grounded in the anthropological concept of a “rite of passage,” creating a secular ritual with therapeutic goals. This framework divides the experience into three distinct phases: separation, liminal, and reincorporation. The “separation” phase corresponds to the preparation period, where participants are guided to disconnect from their daily routines and begin to turn inward. The “liminal” phase is the psilocybin dosing session itself, a period of profound and often transformative experience. Finally, “reincorporation” is the integration phase, where the insights and experiences from the dosing session are processed and woven into the fabric of the participant’s life (1).

What is the Role of the Group in this Therapy?

While most psilocybin clinical trials have focused on individual therapy, this study highlights the potential of a group model. The shared experience can foster a sense of community and mutual support, which is particularly valuable for individuals facing the isolation that often accompanies a cancer diagnosis. The group setting allows participants to witness and learn from each other’s journeys, creating a powerful collective healing experience. The study successfully demonstrated that a facilitator-to-participant ratio of 4 to 8 is safe, paving the way for broader access to this promising therapy (1).

What Are the Implications for the Future of Cancer Care?

The success of this FDA-approved trial marks a significant milestone in the field of psychedelic medicine. It provides a scientifically validated framework for conducting group-based psilocybin therapy in a way that is both safe and effective. As research in this area continues to expand, we may see these ritual-based group retreats become an integral part of a more holistic and compassionate approach to cancer care, addressing not just the physical symptoms of the disease, but the profound emotional and spiritual challenges as well. This approach aligns with the growing recognition of the importance of addressing the whole person in cancer treatment, a sentiment echoed in a 2024 review in the Journal of the Advanced Practitioner in Oncology (4).

Conclusion 

The journey through cancer is fraught with challenges, but innovative therapies like psilocybin-assisted group retreats are opening up new avenues for healing and hope. By combining the power of psychedelic medicine with the ancient wisdom of ritual and the profound support of community, we can begin to address the deep-seated anxiety and depression that so often accompany a cancer diagnosis. If you are struggling with the emotional impact of a serious illness, please know that you are not alone and that there are resources available to help.

At Serenity Professional Counseling, we specialize in helping individuals navigate life’s most difficult challenges, including the trauma and anxiety that can accompany a serious medical diagnosis. We offer a safe and supportive environment to explore your experiences and find a path toward healing. To learn more about our services, including Trauma Therapy and Anxiety Treatment, and to explore how we can support you on your journey, please visit our contact page to schedule a consultation. For further reading on related topics, you might find our blog post on Inner Journeys insightful.

About the Author

This article was written by Jeff Jones, a Licensed Professional Counselor (LPC) in Texas in practice 27 years. He is a 2024 graduate of the CIIS Center for Psychedelic Therapies and Research program. With a compassionate and evidence-based approach, he helps clients navigate life's challenges and find a path toward healing.

Disclaimer

The information in this article, including discussions of psychedelic-assisted psychotherapy, is for informational purposes only. Psychedelic-assisted psychotherapy has not been approved by all regulatory agencies in the United States, and its safety and efficacy are still being established. This content is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

(1) Back, A. L., McGregor, B. A., Billingsley, L., Blom, D., et al. (2026). Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study. Psychedelic Medicine. https://journals.sagepub.com/doi/10.1177/28314425251404460

(2 ) Agrawal, M., et al. (2024). Psilocybin‐assisted group therapy in patients with cancer diagnosed with a major depressive disorder. Cancer. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.35010

(3 ) Lewis, B. R., et al. (2023). A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer. Journal of Pain and Symptom Management. https://www.sciencedirect.com/science/article/abs/pii/S0885392423005304

(4 ) Bellman, V., et al. (2024). Review of Psilocybin Use for Depression among Cancer Patients. Journal of the Advanced Practitioner in Oncology. https://pmc.ncbi.nlm.nih.gov/articles/PMC11083170/